{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:58:40Z","timestamp":1792209520089,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ygyno.2019.12.002","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T08:12:04Z","timestamp":1576829524000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer"],"prefix":"10.1016","volume":"156","author":[{"given":"Rebecca C.","family":"Arend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemyslaw","family":"Chimiczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ygyno.2019.12.002_bb0005","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ijc.23724","article-title":"Borderline ovarian tumors in Sweden 1960\u20132005: trends in incidence and age at diagnosis compared to ovarian cancer","volume":"123","author":"Skirnisdottir","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"9 Suppl. 3","key":"10.1016\/j.ygyno.2019.12.002_bb0010","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/IGC.0000000000000282","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)","volume":"24","author":"Harter","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2019.12.002_bb0015","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0893-3952(22)04457-X","article-title":"Borderline epithelial tumors of the ovary","volume":"18","author":"Hart","year":"2005","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.002_bb0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00003081-200609000-00011","article-title":"Borderline ovarian tumors: current concepts for prognostic factors and clinical management","volume":"49","author":"Jones","year":"2006","journal-title":"Clin. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.002_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/gyno.2002.6711","article-title":"Long-term survival and patterns of care in women with ovarian tumors of low malignant potential","volume":"86","author":"Trimble","year":"2002","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.002_bb0030","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ygyno.2005.03.013","article-title":"Fifth international conference on ovarian cancer: challenges and opportunities","volume":"97","author":"Sood","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2019.12.002_bb0035","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IGC.0000000000000257","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas","volume":"24","author":"Gourley","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.002_bb0040","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3802\/jgo.2018.29.e15","article-title":"Trends of low-grade serous ovarian carcinoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.002_bb0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","article-title":"Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary","volume":"108","author":"Gershenson","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.002_bb0050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ajog.2008.01.035","article-title":"Epidemiology of low-grade serous ovarian cancer","volume":"198","author":"Plaxe","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.002_bb0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.002_bb0060","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. an analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.002_bb0065","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.002_bb0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.002_bb0075","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.12.002_bb0080","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000190","article-title":"Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer","volume":"24","author":"Grisham","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.002_bb0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2017.01.027","article-title":"Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience","volume":"145","author":"Dalton","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2019.12.002_bb0090","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.002_bb0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ctrv.2014.12.003","article-title":"Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy","volume":"41","author":"Della Pepa","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.002_bb0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ygyno.2017.01.023","article-title":"Recurrent low grade serous ovarian cancer in a 20 year old woman: a case from the Ohio State University College of Medicine","volume":"144","author":"Cohn","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.002_bb0105","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ygyno.2013.05.021","article-title":"Low-grade serous carcinoma: new concepts and emerging therapies","volume":"130","author":"Romero","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.12.002_bb0110","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"issue":"7353","key":"10.1016\/j.ygyno.2019.12.002_bb0115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.002_bb0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2019.12.002_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.gore.2018.05.011","article-title":"Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment","volume":"25","author":"Han","year":"2018","journal-title":"Gynecol. Oncol. Rep."},{"issue":"22","key":"10.1016\/j.ygyno.2019.12.002_bb0130","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1158\/1078-0432.CCR-18-0494","article-title":"Phase Ib study of binimetinib with paclitaxel in patients with platinum-resistant ovarian cancer: final results, potential biomarkers, and extreme responders","volume":"24","author":"Grisham","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2019.12.002_bb0135","series-title":"Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6\u201310","article-title":"Combi- nation of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K\/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: results of a phase Ib dose-escalation trial [abstract]","author":"Infante","year":"2013"},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.002_bb0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2019.12.002_bb0145","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2019.12.002_bb0150","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ygyno.2019.12.002_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(00)00369-5","article-title":"Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report","volume":"37","author":"Cull","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2019.12.002_bb0160","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2019.12.002_bb0165","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00451727","article-title":"Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer","volume":"3","author":"Osoba","year":"1994","journal-title":"Qual. Life Res."},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.002_bb0170","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.12.002_bb0175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/JGO.2015.000802","article-title":"Risk of selected cardiovascular toxicities in patients with cancer treated with MEK inhibitors: a comparative systematic review and meta-analysis","volume":"1","author":"Abdel-Rahman","year":"2015","journal-title":"J. Glob. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2019.12.002_bb0180","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-014-0088-2","article-title":"Dermatological toxicity associated with targeted therapies in cancer: optimal management","volume":"15","author":"Peuvrel","year":"2014","journal-title":"Am. J. Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.12.002_bb0185","first-page":"249","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J. Clin."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581931786X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581931786X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:49:16Z","timestamp":1758772156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581931786X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S009082581931786X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}